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Conclusions Guideline adherence for secondary prevention 
medication following acute coronary syndrome was sub-
stantial; however, variation between hospitals and patient 
groups was found. Efforts to increase guideline adherence 
can focus on underperforming hospitals and undertreated 
patient groups.
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Background
In recent years, the in-hospital survival rates of patients with 
an acute coronary syndrome (ACS) have increased [1], yet 
patients with a history of ACS are at higher risk of adverse 
cardiac outcomes in the future [2]. As a result, discharge 
and post-discharge management, comprising referral to a 
cardiac rehabilitation program and the prescription of sec-
ondary prevention medication [3, 4], have become more 
important in ACS care.
Prescribing medication for secondary prevention of 
adverse cardiac outcomes after discharge from the hospi-
tal is recommended by the European Society of Cardiology 
guidelines on the management of ACS. This medication 
comprises a combination of acetylsalicylic acid, P2Y12 
receptor inhibitor, statin, beta-blocker and angiotensin-con-
verting enzyme (ACE) inhibitor [3, 4] However, previous 
studies have identified non-adherence to these guideline rec-
ommendations in several patient groups [5, 6]. As a result, 
these patients have a higher but potentially preventable risk 
of adverse outcomes after discharge [7].
Monitoring and improving guideline adherence for second-
ary prevention medication at hospital discharge has the poten-
Abstract
Background The prescription of guideline-recommended 
medication for secondary prevention after acute coronary 
syndrome has been suboptimal in the past. In the present 
study, guideline adherence and associated patient, care and 
hospital characteristics at hospital discharge after acute cor-
onary syndrome were studied.
Methods Charts of patients with acute coronary syndrome 
discharged from 13 Dutch hospitals in 2012 were reviewed. 
Guideline adherence was defined as the prescription of 
acetylsalicylic acid, P2Y12 receptor inhibitor, statin, beta-
blocker and angiotensin-converting enzyme (ACE) inhibi-
tor at discharge, or a documented contraindication. Associ-
ated characteristics were identified by means of generalized 
linear mixed models for binary outcomes.
Results In total, 2471 patients were included. Complete 
guideline adherence was achieved in 69.1 % of the patients, 
ranging from 42.1 to 87.0 % between hospitals. The ACE 
inhibitor was most often missing (21.2 %). Patients with 
non-ST-segment elevation myocardial infarction or unsta-
ble angina, patients with a history of coronary artery bypass 
grafting or elderly women were less likely to be discharged 
with the guideline-recommended medication.
J. Tra () · I. van der Wulp · M.C. de Bruijne · C. Wagner
Department of Public and Occupational health,  
EMGO+/VU University medical center,
van der Boechorststraat 7,
1081 BT Amsterdam, The Netherlands
e-mail: j.tra@vumc.nl
Y. Appelman
Department of Cardiology, VU University medical center,
Amsterdam, The Netherlands
C. Wagner




Neth Heart J (2015) 23:214–221
tial to improve the quality of care and further reduce adverse 
outcomes in patients with ACS [8, 9]. This was recognised by 
Dutch cardiology care providers, who included a focus on dis-
charge medication in a national quality improvement program 
[10]. In this study we investigated guideline adherence and 
associated patient, care and hospital characteristics for sec-
ondary prevention medication at discharge from the hospital 
for patients with ACS in the Netherlands during implementa-
tion of a nationwide quality improvement program.
Methods
A detailed description of the study design, methods and the qual-
ity improvement program has previously been published [11].
Design
The study was conducted in a cross-sectional design.
Setting and Inclusion
In 2012, 91 hospitals provided ACS care in the Netherlands. 
From this pool, 13 hospitals were selected by means of a 
multistage random sampling procedure to participate in the 
evaluation of the national quality improvement program.
Potentially eligible study charts were selected from the 
hospitals’ financial system codes for ST-segment elevation 
myocardial infarction (STEMI), non-ST-segment elevation 
myocardial infarction (NSTEMI) and unstable angina (UA). 
All patients discharged in 2012 with a diagnosis of ACS 
(as confirmed in the discharge letter) were considered for 
inclusion. Charts of patients transferred to another hospital 
or department for further evaluation or treatment, patients 
who died during hospital admission, who received palliative 
care, who left the hospital against medical advice or who 
had no information about the prescribed medication at dis-
charge in their chart were excluded.
Data collection and processing
Data were collected by means of retrospective chart review. 
The chart reviewers visited the participating hospitals monthly. 
When the number of charts exceeded the screening capacity, 
charts were selected per month in chronological order of dis-
charge until the screening capacity limit was reached.
In this study, guideline adherence was defined as the 
prescription of acetylsalicylic acid, P2Y12 receptor inhibi-
tor, statin, beta-blocker and ACE inhibitor at discharge, 
or a documented contraindication or other motivation for 
not prescribing these medicines. From the charts, informa-
tion related to the prescription of these five medicines was 
abstracted. In case one or more medicines were not pre-
scribed, documented contraindications as reported in an 
annually updated Dutch database of pharmacotherapy [12], 
or as motivated by the treating physician were retrieved 
(e.g. the prescription of anticoagulants instead of acetylsali-
cylic acid). The full list of contraindications was reported 
previously [11]. Additionally, patient, care and hospital 
characteristics (n = 40), e.g. age, sex, cardiac medical his-
tory, risk factors, resuscitation and discharge diagnosis were 
recorded. Hospitals were characterised by type (academic, 
tertiary teaching or general) and presence of percutaneous 
coronary intervention (PCI) and/or coronary artery bypass 
grafting (CABG) facilities (yes/no).
A sample of the charts (n = 149 (6.0 %)) was screened 
by two chart reviewers independently and the percentage 
of agreement between the reviewers was calculated. The 
results were satisfactory, with all 40 variables above 85 % 
agreement indicating good to excellent data reliability.
Missing data
In total, 0.82 % of the data were missing, ranging per vari-
able from 0.04 % (date of discharge) to 2.5 % (heart failure 
or arrival). Little’s test [13] was non-significant (p = 0.57) and 
missing value analyses showed no relationship between the 
missing data and the complete data, indicating the missing 
data were missing completely at random [14]. Therefore miss-
ing data were imputed by means of full conditional specifica-
tion using the imputation procedure in IBM SPSS (Version 20 
for Windows). As a sensitivity analysis, the results of the final 
analysis were compared with the results of a full case analysis 
to determine the accuracy of the imputation procedure.
Analysis
Characteristics of the study population, participating hos-
pitals and guideline adherence were determined by means 
of descriptive statistics. Associations of predictor variables 
with guideline adherence (complete adherence vs incom-
plete adherence) were studied by means of generalized 
linear mixed models for binary outcomes. To correct for 
clustering of patients within hospitals, hospital was entered 
as random effect in the analyses.
The associations of the predictor variables with guide-
line adherence were tested in univariate models (Table 1). 
All predictor variables with a significant association 
(p ≤ 0.05) were added to a multivariable model. To account 
for collinearity, all predictor variables without a significant 
association in the univariate analyses were added to the 
multivariable model one by one. In case of a significant 
improvement of the model fit (p ≤ 0.05), they were added 
to the multivariable model. Additionally, several potential 
interactions between variables were tested in the multivari-
able model: age with treatment, discharge diagnosis and 
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Table 1 Associations of patient, arrival, discharge and hospital characteristics with prescription of discharge medication in univariable generalized 
linear mixed models (N = 2471)






STEMI 910 (36.8 %) 161 (21.1 %) 749 (43.9 %)
NSTEMI 987 (39.9 %) 310 (40.6 %) 677 (39.6 %)
UA 574 (23.2 %) 292 (38.3 %) 282 (16.5 %)
Type of treatment ***< 0.001
Medication 793 (32.1 %) 355 (46.5 %) 438 (25.6 %)
PCI 1552 (62.8 %) 360 (47.2 %) 1192 (69.8 %)
CABG 126 (5.1 %) 48 (6.3 %) 78 (4.6 %)
Age in years (mean, 95 % 
CI)
66.9 (66.4–67.4) 65.9 (65.3–66.5) 69.1 (68.1–70.0) ***< 0.001
Female 801 (32.4 %) 287 (37.6 %) 514 (30.1 %) ***< 0.001
Admission
Resuscitation 100 (4.0 %) 9 (1.2 %) 91 (5.3 %) ***< 0.001
Heart failure on arrival 138 (5.6 %) 35 (4.6 %) 103 (6.0 %) 0.29
Cardiogenic shock on 
arrival
35 (1.4 %) 11 (1.4 %) 24 (1.4 %) 0.79
Transportation from an-
other hospital
394 (15.9 %) 97 (12.7 %) 297 (17.4 %) **0.002
Discharge
Month of discharge N/A N/A N/A 0.22
Weekend discharge 724 (29.3 %) 226 (29.6 %) 498 (29.2 %) 0.85
Length of stay (median 
days, 1st-3rd quartile)b
5 (3–7) 5 (4–7) 4 (3–6) ***< 0.001
Risk factors
Diabetes mellitus 545 (22.1 %) 118 (15.5 %) 427 (25.0 %) ***< 0.001
Hypertension 1204 (48.7 %) 389 (51.0 %) 815 (47.7 %) 0.10
Kidney failure 111 (4.5 %) 22 (2.9 %) 89 (5.2 %) *0.02
Chronic heart failure 103 (4.2 %) 31 (4.1 %) 72 (4.2 %) 0.61
Positive family history 910 (36.8 %) 281 (36.8 %) 629 (36.8 %) 0.64
Coronary stenosis 205 (8.3 %) 79 (10.4 %) 126 (7.4 %) **0.003
Hyperlipidaemiac 1208 (48.9 %) 375 (49.1 %) 833 (48.8 %) 0.61
Obesity (BMI > 30 kg/m2) 270 (10.9 %) 80 (10.5 %) 190 (11.1 %) 0.64
Smoker 739 (29.9 %) 184 (24.1 %) 555 (32.5 %) ***< 0.001
Former smoker 452 (18.3 %) 138 (18.1 %) 314 (18.4 %) 0.99
Cardiac medical history
Angina pectoris 442 (17.9 %) 167 (21.9 %) 275 (16.1 %) **0.001
Peripheral vascular disease 159 (6.4 %) 50 (6.6 %) 109 (6.4 %) 0.69
Coronary artery disease 264 (10.7 %) 96 (12.6 %) 168 (9.8 %) *0.03
Prior MI 574 (23.2 %) 189 (24.8 %) 385 (22.5 %) 0.21
Prior PCI 592 (24.0 %) 206 (27.0 %) 386 (22.6 %) *0.02
Prior CABG 303 (12.3 %) 125 (16.4 %) 178 (10.4 %) ***< 0.001
Recent PCI, CABG or 
MI (< 6 months before 
admission)
142 (5.7 %) 42 (5.5 %) 100 (5.9 %) 0.51
Hospital characteristics
Type of hospital 0.26
General hospital (n = 4) 648 (26.2 %) 245 (32.1 %) 403 (23.6 %)
 Tertiary teaching hospital 
(n = 7)
1426 (57.7 %) 430 (56.4 %) 996 (58.3 %)
Academic hospital (n = 2) 397 (16.1 %) 88 (11.5 %) 309 (18.1 %)
Treated in hospital with 
PCI facilities (n = 7)
1512 (61.2 %) 448 (58.7 %) 1064 (62.3 %) 0.73
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nation of the five medicines ranged from 42.1 to 87.0 % 
between hospitals. Prescription rates and guideline adher-
ence are presented in Table 2 and Fig. 1.
Factors associated with (in)complete guideline adherence
In univariate generalized linear mixed model analyses, dis-
charge diagnosis, type of treatment, age, sex, resuscitation, 
transport from another hospital and length of stay were signif-
icantly associated with the probability of guideline adherence 
(Table 1). Additionally, the risk factors diabetes mellitus, kid-
ney failure, a prior detected coronary stenosis, current smok-
ing, and a medical history of angina pectoris, coronary artery 
disease, prior PCI or prior CABG were associated with the 
probability of guideline adherence. These were entered in 
a multivariable model. The variable ‘recent PCI, CABG or 
myocardial infarction (< 6 months before admission)’ signifi-
cantly improved the multivariable model fit and was therefore 
subsequently added to the model secondarily. In addition, an 
interaction between age and sex was added to the multivari-
able model. No significant associations between hospital 
characteristics and guideline adherence were found.
In the final model, patients with NSTEMI or UA com-
pared with patients with STEMI, and patients who had a 
prior CABG were less likely to receive the guideline-recom-
mended medication at discharge (Table 3). Further, adher-
ence was higher for patients who were treated with PCI 
compared with patients who received pharmacological or 
CABG treatment, who had diabetes mellitus or kidney fail-
ure, who were resuscitated on admission, who had longer 
lengths of hospital stay, or who had a recent PCI, CABG or 
myocardial infarction (< 6 months before admission). Addi-
tionally, the effect of age differed between men and women, 
i.e. the medication was less likely completely according to 
the guidelines for older women compared with older men.
Sensitivity analysis
As a sensitivity analysis the current model was compared 
with a full case analysis model (n = 2253). No differences 





 Treated in hospital with 
CABG facilities (n = 5)
958 (38.8 %) 290 (38.0 %) 668 (39.1 %) 0.87
*significant at ≤ 0.05 level; **significant at ≤ 0.01 level; ***significant at ≤ 0.001 level
STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, UA unstable angina pectoris, 
PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, CI confidence interval, N/A not applicable, BMI body mass 
index, MI myocardial infarction
aP-values are calculated using the Wald statistic, comparing the model fit of a generalized linear mixed model with and without the variable, 
corrected for clustering of patients in hospitals
bLength of stay was log-transformed after careful consideration of the residuals of a model without random intercept
cHyperlipidaemia was defined as described in patients history or statin use before admission
Table 1 (continued)
sex; and discharge diagnosis with treatment and sex. In case 
of a significant improvement of the model fit (p ≤ 0.05), the 
interactions were added to the multivariable model. From 
this model, the fixed effects were presented as odds ratios 
(OR) with 95 % confidence intervals (CI).
The data were analysed in R (version 3.0.2 for Windows) 
using the lme4 package.
Ethical approval
The study protocol was approved by the medical ethics 
review committee of the VU University medical center.
Results
Selection of patient charts
In total, 3427 charts of patients with a confirmed discharge 
diagnosis of ACS in 2012 were screened. Of these, 876 
patients (26.6 %) were transferred to another hospital or 
department for further evaluation or treatment, 56 (1.6 %) 
died during admission, information concerning discharge 
medication was missing for 14 patients (0.4 %), 6 (0.2 %) left 
the hospital against medical advice and 4 (0.1 %) received 
palliative care. After exclusion of these charts, 2471 patients 
were eligible for further analyses. Their mean age was 66.9 
years and the majority were male (67.6 %) (Table 1).
Guideline adherence
Overall, 49.1 % of the patients were prescribed all five 
guideline-recommended medicines at discharge from the 
hospital, while an additional 20.0 % had contraindications 
documented for the medicines that were not prescribed. 
Consequently, the complete guideline adherence for the 
combination of the five medicines was 69.1 %. Guideline 
adherence for the individual medicines ranged between 
99.6 % for acetylsalicylic acid and 76.8 % for the ACE 
inhibitor. Complete guideline adherence for the combi-
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acetylsalicylic acid and the lowest for the ACE inhibitor. 
Several patient and care characteristics were significantly 
associated with guideline adherence, while hospital charac-
teristics were not.
The level of complete guideline adherence found in this 
study was comparable with another Dutch study in which 
65.2 % of the patients with ACS were discharged with the 
recommended secondary prevention discharge medication 
[15]. Also, in accordance with other studies, guideline adher-
ence for the recommended discharge medication was lowest 
were found in variable selection or significant associations, 
indicating a reliable imputation procedure.
Discussion
In this multicentre study, guideline adherence for second-
ary prevention medication prescription at hospital discharge 
for patients with ACS was investigated. Complete guide-
line adherence was 69.1 %, with the highest adherence for 
 Table 2 Prescription patterns for the five medicines for secondary prevention (N = 2471)




Range (% in lowest – 
highest scoring hospital)
Acetylsalicylic acid 2271 (91.9 %) 86.6–97.2 % 2460 (99.6 %) 98.6–100 %
P2Y12 receptor inhibitor 2189 (88.6 %) 70.3–95.9 % 2293 (92.8 %) 75.7–98.6 %
Statin 2294 (92.8 %) 81.1–97.4 % 2363 (95.6 %) 83.8–98.9 %
Beta-blocker 2220 (89.8 %) 83.5–99.0 % 2360 (95.5 %) 90.5–99.0 %
ACE inhibitor 1603 (64.9 %) 47.5–74.5 % 1898 (76.8 %) 57.9–93.1 %
All 5 medicines 1214 (49.1 %) 28.2–59.0 % 1708 (69.1 %) 42.1–87.0 %
4 out of 5 medicines 2068 (83.7 %) 67.8–91.0 % 2297 (93.0 %) 78.4–99.0 %
ACE angiotensin-converting enzyme, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial 
infarction, UA unstable angina pectoris
aGuideline adherence refers to either prescription of the medicine or documentation of a contraindication
Fig. 1 Guideline adherence (%) per medicine per discharge diagno-
sis. ASA acetylsalicylic acid, P2Y12 P2Y12 receptor inhibitor, ST statin, 
BB beta-blocker, ACE angiotensin-converting enzyme inhibitor, ACS 
acute coronary syndrome, STEMIST-elevation myocardial infarction, 
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pitals, thereby reducing the effective sample size [18]. 
When no statistical correction for clustering is used, the 
hospital characteristics are attributed to individual patients 
(n = 2471) instead of hospitals (n = 13), resulting in spuri-
ous significant results.
The odds of complete guideline adherence were lowest 
for patients with UA, intermediate for NSTEMI patients and 
highest for patients with STEMI. This finding confirms the 
results of previous studies [19, 20]. The difference in guide-
line adherence between STEMI and NSTEMI/UA might be 
explained by small differences in the European Society of 
Cardiology guidelines for the management of ACS patients 
with and without ST-segment elevation. One difference is the 
recommendation to prescribe a beta-blocker to all patients 
with STEMI, while only to patients with NSTEMI/UA who 
have LV dysfunction. However, this difference in the guide-
lines does not explain the differences found in the present 
study, as the differences between STEMI and NSTEMI/
UA were mostly caused by lower guideline adherence for 
the ACE inhibitor and the P2Y12 inhibitor. Moreover, the 
high prescription rates of beta-blockers in NSTEMI and UA 
patients might indicate overmedication or adherence, poten-
tially caused by adherence to previous guidelines [21] as 
guideline adoption takes time.
Interestingly, the negative association of age with guide-
line adherence was stronger in women than in men. This 
finding is worrisome, as the most recent European guide-
lines recommend managing both genders in a similar fash-
ion [22]. To our knowledge, there is limited information on 
the impact of sex and age on the decision of physicians to 
prescribe secondary prevention medication after acute coro-
nary syndrome. Therefore, additional research is required 
to identify potential (reasons for) treatment biases of physi-
cians towards treatment of elderly women.
Since the estimated guideline adherence for secondary 
prevention medication after ACS was substantial, it would 
be recommended to focus future quality improvement 
efforts on reducing variation between patient groups and 
between hospitals. Several interventions exist for improv-
ing guideline adherence, e.g. feedback of performance [23], 
continuing education [24] or integrated care [25]. These 
interventions can focus on undertreated patient groups, e.g. 
facilitating educational meetings for cardiology care provid-
ers about the treatment of elderly women with ACS.
Limitations
Several limitations of this study might influence interpreta-
tion of its results.
Having no information on one of the medicines pre-
scribed at discharge in the patient chart can be the result 
of no prescription, or no documentation of the prescription, 
for the ACE inhibitor [16]. This finding may be explained 
by the recommendation to prescribe the ACE inhibitor to 
all patients with ACS, but an exception may be made for 
normotensive patients without heart failure, left ventricu-
lar (LV) dysfunction or diabetes mellitus [4]. Furthermore, 
an angiotensin-II-receptor inhibitor can be prescribed as 
an alternative for the ACE inhibitor, although the ACE 
inhibitor is the primary choice, as previous studies showed 
superiority in reducing adverse outcomes [17]. Therefore, 
prescription of an angiotensin-II-receptor inhibitor was not 
abstracted from the charts in this study.
Although there was substantial variation in guideline 
adherence between hospitals, this could not be explained 
by the hospitals’ characteristics (presence of interven-
tion facilities and type of hospital). A recent study found 
that hospitals with interventional facilities treated more 
patients according to the guidelines [15]. The different 
findings in this study might be explained by the use of 
a statistical correction for clustering of patients in hos-
Table 3 Associations of patient, arrival, discharge and hospital char-
acteristics with prescription of secondary prevention medication in the 
multivariable generalized linear mixed model
Variable OR (95 % CI) P-value
Discharge diagnosis
 STEMI (intercept) N/A 0.37
 NSTEMI 0.64 (0.49–0.82) ***< 0.001
 UA 0.29 (0.21–0.39) ***< 0.001
Female patient 4.09 (1.32–12.7) **< 0.01
Coronary artery disease 1.13 (0.79–1.61) 0.51
Angina pectoris 1.04 (0.79–1.38) 0.76
Prior PCI 0.98 (0.76–1.26) 0.87
Prior CABG 0.70 (0.51–0.95) *0.02
Diabetes mellitus 2.67 (2.06–3.45) ***< 0.001
Kidney failure 2.10 (1.23–3.57) *0.007
Smoker 1.19 (0.94–1.50) 0.16
Coronary stenosis 0.82 (0.56–1.20) 0.30
Resuscitation 2.65 (1.29–5.44) **0.008
Transportation from another 
hospital
0.81 (0.60–1.10) 0.18
Age 0.97 (0.96–0.99) ***< 0.001
Length of staya 1.43 (1.19–1.72) ***< 0.001
PCI 2.05 (1.63–2.59) ***< 0.001
CABG 0.98 (0.63–1.55) 0.94
Recent PCI, CABG or MI 
(< 6 months before admission)
1.91 (1.23–2.95) **0.004
Interaction between Age and Sex 1.02 (1.00–1.04) **0.003
*significant at ≤ 0.05 level; **significant at ≤ 0.01 level; ***significant 
at ≤ 0.001 level
STEMI ST-segment elevation myocardial infarction, N/A not 
applicable, NSTEMI non-ST-segment elevation myocardial 
infarction, UA unstable angina pectoris, PCI percutaneous coronary 
intervention, CABG coronary artery bypass grafting, MI myocardial 
infarction
aLength of stay was log-transformed after careful consideration of 
the residuals of a model without random intercept
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patient groups who receive suboptimal treatment at dis-
charge from the hospital, e.g. elderly women and patients 
with NSTEMI or UA.
Acknowledgements We would like to thank all participating PCI 
centres, cardiologists and quality officers for their cooperation in the 
data collection.
Funding This work was supported by the Dutch Ministry of Health, 
Welfare and Sport.
Conflict of interest None declared.
Open Access This article is distributed under the terms of the Creative 
Commons Attribution License which permits any use, distribution, and 
reproduction in any medium, provided the original author(s) and the 
source are credited.
References
 1. Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and 
heart failure in acute coronary syndromes, 1999–2006. JAMA. 
2007;297:1892–900.
 2. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction 
model for all forms of acute coronary syndrome: estimating the 
risk of 6-month postdischarge death in an international registry. 
JAMA. 2004;291:2727–33.
 3. Van de Werf F, Bax J, Betriu A, et al. Management of acute myo-
cardial infarction in patients presenting with persistent ST-seg-
ment elevation: the task force on the management of ST-Segment 
Elevation Acute Myocardial Infarction of the European Society of 
Cardiology. Eur Heart J. 2008;29:2909–45.
 4. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the 
management of acute coronary syndromes in patients presenting 
without persistent ST-segment elevation: the task force for the 
management of acute coronary syndromes (ACS) in patients pre-
senting without persistent ST-segment elevation of the European 
Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054.
 5. Bauer T, Gitt AK, Junger C, et al. Guideline-recommended sec-
ondary prevention drug therapy after acute myocardial infarction: 
predictors and outcomes of nonadherence. Eur J Cardiovasc Prev 
Rehabil. 2010;17:576–81.
 6. Kotseva K, Wood D, De Backer G, De Bacquer D. Use and effects 
of cardiac rehabilitation in patients with coronary heart disease: 
results from the EUROASPIRE III survey. Eur J Prev Cardiol. 
2013;20:817–26.
 7. Chew DP, Huynh LT, Liew D, Astley C, Soman A, Brieger D. 
Potential survival gains in the treatment of myocardial infarction. 
Heart. 2009;95:1844–50.
 8. Peterson ED, Roe MT, Mulgund J, et al. Association between 
hospital process performance and outcomes among patients with 
acute coronary syndromes. JAMA. 2006;295:1912–20.
 9. Jernberg T, Johanson P, Held C, Svennblad B, Lindback J, Wallen-
tin L. Association between adoption of evidence-based treatment 
and survival for patients with ST-elevation myocardial infarction. 
JAMA. 2011;305:1677–84.
10. VMS veiligheidsprogramma [VMS safety management program]. 
Optimale zorg bij acute coronaire syndromen [Optimal care for 
acute coronary syndromes]. 2010. http://www.vmszorg.nl/.
11. Tra J, Engel J, van der Wulp I, de Bruijne MC, Wagner C. Moni-
toring guideline adherence in the management of acute coronary 
syndrome in hospitals: design of a multicentre study. Neth Heart J. 
2014;22:346–53.
contraindication or another reason for not prescribing the 
medicine (e.g. preserved LV function for the ACE inhibi-
tor). As the charts were not screened by physicians, implicit 
decisions could not be included in the chart review. Instead, 
a standard list of contraindications was used, thus mini-
mising inter-reviewer variation. Consequently, the rates of 
guideline adherence in this study might differ slightly from 
real-life guideline adherence and are therefore only an esti-
mate. An additional limitation relating to documentation 
is the selection of patients by means of the hospital billing 
systems with manual review of the discharge diagnosis in 
the chart. Potentially some ACS patients were missed who 
received a billing code not related to ACS or with a different 
discharge diagnosis documented in their chart, which could 
limit the external validity of the findings in this study.
Another limitation of this study was that the potential 
prescription of suboptimal doses of medicines was counted 
as adhering to the guidelines [26] As optimal doses tend to 
differ between patients, and the optimal dose can often not 
be prescribed at discharge, it was not possible to incorporate 
doses in this study. Counting suboptimal doses as guideline 
adherence may have led to an overestimation of the qual-
ity of care in this study. In addition, prescribing medicines 
that are not indicated can also be considered to be incom-
plete guideline adherence. However, as the charts were not 
screened by physicians, this could not be taken into account 
in this study.
Prescription behaviour of individual physicians can be an 
additional source of variation in guideline adherence [27]; 
however, in this study it was not feasible to identify the phy-
sician responsible for medication prescription at discharge 
from the charts.
As a result of the large number of patients in PCI cen-
tres, the screening capacity limited the number of included 
patient charts per month. However, this should not have 
affected the results in our study since patients were selected 
in chronological order of discharge and there was no dif-
ference in guideline adherence between hospitals with and 
without PCI and/or CABG facilities.
Finally, participation in a national quality improvement 
program and the monthly measurements might have over-
estimated guideline adherence. However, the effect of this 
program on guideline adherence is expected to be limited as 
no significant association between month of discharge and 
guideline adherence was found.
Conclusion
Guideline adherence concerning the prescription of dis-
charge medication in the Netherlands is substantial though 
differs between hospitals and patient groups. Efforts to fur-
ther improve guideline adherence can be targeted on those 
221
1 3
Neth Heart J (2015) 23:214–221
20. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Gold-
berg RJ. Recent trends in the incidence, treatment, and outcomes 
of patients with STEMI and NSTEMI. Am J Med. 2011;124:40–7.
21. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute 
coronary syndromes in patients presenting without persistent ST-
segment elevation. Eur Heart J. 2002;23:1809–40.
22. Steg PG, James SK, Atar D, et al. ESC Guidelines for the man-
agement of acute myocardial infarction in patients presenting with 
ST-segment elevation. Eur Heart J. 2012;33:2569–619.
23. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects 
on professional practice and healthcare outcomes. Cochrane Data-
base Syst Rev. 2012;6:Cd000259.
24. Forsetlund L, Bjorndal A, Rashidian A, et al. Continuing edu-
cation meetings and workshops: effects on professional prac-
tice and health care outcomes. Cochrane Database Syst Rev. 
2009;2:Cd003030.
25. Liem SS, van der Hoeven BL, Oemrawsingh PV, et al. MISSION!: 
optimization of acute and chronic care for patients with acute myo-
cardial infarction. Am Heart J. 2007;153:14.e1–11.
26. Arnold SV, Spertus JA, Masoudi FA, et al. Beyond medication 
prescription as performance measures: optimal secondary preven-
tion medication dosing after acute myocardial infarction. J Am 
Coll Cardiol. 2013;62:1791–801.
27. Margulis AV, Choudhry NK, Dormuth CR, Schneeweiss S. Varia-
tion in initiating secondary prevention after myocardial infarction 
by hospitals and physicians, 1997 through 2004. Pharmacoepide-
miol Drug Saf. 2011;20:1088–97.
12. Dutch Health Insurance Counsil. Pharmacotherapeutic Compass. 
2012. http://www.fk.cvz.nl/.
13. Little RA. Test of missing completely at random for multivariate 
data with missing values. J Am Stat Assoc. 1988;83:1198–202.
14. Rubin D. Inference and missing data. Biometrika. 1976;63:581–92.
15. Yetgin T, van der Linden MM, de Vries AG, et al. Current dis-
charge management of acute coronary syndromes: data from the 
Rijnmond Collective Cardiology Research (CCR) study. Neth 
Heart J. 2014;22:20–7.
16. Pedone C, Di Pasquale G, Greco C, et al. Prescription at discharge 
of recommended treatments for secondary prevention in patients 
with ST-segment elevation myocardial infarction according to 
reperfusion strategies. Results from the IN-ACS outcome study. 
Acute Card Care. 2009;11:222–8.
17. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis report-
ing effects of angiotensin-converting enzyme inhibitors and an-
giotensin receptor blockers in patients without heart failure. J Am 
Coll Cardiol. 2013;61:131–42.
18. Austin PC, Tu JV, Alter DA. Comparing hierarchical modeling 
with traditional logistic regression analysis among patients hos-
pitalized with acute myocardial infarction: should we be ana-
lyzing cardiovascular outcomes data differently? Am Heart J. 
2003;145:27–35.
19. Somma KA, Bhatt DL, Fonarow GC, et al. Guideline adher-
ence after ST-segment elevation versus non-ST segment el-
evation myocardial infarction. Circ Cardiovasc Qual Outcomes. 
2012;5:654–61.
